While high-quality public datasets from Pythia are valuable for drug discovery, finding cohorts that match specific therapeutic questions is notoriously difficult. Public repositories are often limited by disease representation, sparse treatment metadata, and small patient sizes. The Pythia-Lexogen partnership directly eliminates these hurdles, unifying advanced analytics and standardized data curation workflows with Lexogen’s streamlined, custom wet-lab data generation.
The integrated Pythia ecosystem accelerates drug discovery by guiding researchers through three distinct phases of data exploration and experimental design. First, teams leverage Pythiomics to access fully curated, high-quality, and harmonized multi-omic public datasets. To fill specific data gaps, researchers can query the Pythia Data Forge, an incubator repository housing hundreds of thousands of searchable datasets that can be manually quality-controlled and finalized in under a week to expand the active cohort. By blending these comprehensive, criteria-matched datasets, scientists can pinpoint the critical biological signals needed to accurately inform future experiments. Finally, through the Pythia Data Universe, teams can source optimized biobank samples and connect with premier multi-omics wet-lab providers, allowing them to precisely execute custom bulk and single-cell RNA-seq (scRNA-seq) experiments powered by Lexogen.
“Lexogen’s twenty years of proven data excellence and their ability to execute on projects exceeding 100,000 samples make them the ideal partner for Pythia,” stated Tristan Gill, CEO of Pythia BioSciences. “Together, we are empowering the scientific community to accelerate drug discovery and deliver life-changing therapies to the patients who need them most.”
Stéphane Barges, CEO of Lexogen, also added: “By combining our sequencing expertise with Pythia’s rigorous data harmonization and curation pipeline, we hope to expand both the quantity and diversity of high-quality RNA-seq datasets available to researchers. Ultimately, this will enable more data-driven research with broader biological insights and accelerate more discoveries.”
For more information about the collaboration, please contact Pythia Biosciences at www.pythiabio.com or Lexogen at www.lexogen.com.
About Pythia Biosciences
Pythia BioSciences is a leading provider of multi-omics software, curated content, and advanced bioinformatics services designed to streamline data-driven drug discovery. By combining Pythiomics, a meticulously harmonized multi-omic database, with the C-DIAM Multi-Omics Studio analytical platform and advanced API for cross-database queries and programmatic analysis, Pythia helps scientists get the accurate biological insights they need to accelerate drug discovery and development. The company’s unique technology ecosystem empowers biopharmaceutical teams to rapidly turn disparate biological datasets into actionable therapeutic insights. To learn more, visit www.pythiabio.com.
About Lexogen
Lexogen is an Austrian biotechnology company specializing in RNA sequencing and transcriptomics. With nearly 20 years of expertise, the company develops tools and provides scalable sequencing services for both single-cell and bulk RNA applications, supporting virtually any sample type used in transcriptomics research. Widely recognized as the inventor of 3′ mRNA sequencing, Lexogen has demonstrated the ability to process more than 100,000 samples while maintaining rigorous quality standards. This scalability complements Pythia’s expanding data ecosystem, enabling the partnership to support large-scale transcriptomics projects from sample sequencing to analysis-ready datasets. Lexogen operates under ISO 13485 and GCLP. https://www.lexogen.com/